The HIV-1 envelope glycoprotein gp120 is heavily glycosylated and bears numerous high mannose sugars. These sugars can serve as targets for HIV-inactivating compounds, such as antibodies and lectins, which bind to the glycans and interfere with viral entry into the target cell. We determined the 1.6 Å x-ray structure of Cyt-CVNH, a recently identified lectin from the cyanobacterium Cyanothece 7424 , and elucidated its glycan specificity by NMR. The Cyt-CVNH structure and glycan recognition profile are similar to those of other CVNH proteins, with each domain specifically binding to Man␣(1-2)Man␣ units on the D1 and D3 arms of high mannose glycans. However, in contrast to CV-N, no cross-linking and precipitation of the crosslinked species in solution was observed upon Man-9 binding, allowing, for the first time, investigation of the interaction of Man-9 with a member of the CVNH family by NMR. HIV assays showed that Cyt-CVNH is able to inhibit HIV-1 with ϳ4-fold higher potency than CV-N P51G , a stabilized version of wild type CV-N. Therefore, Cyt-CVNH may qualify as a valuable lectin for potential microbicidal use.Despite the effective use of anti-retroviral therapies as a means to treat HIV infection and prolong the lifespan of those affected by AIDS, the number of HIV infections worldwide continues to grow. Unfortunately, at present, no vaccine is available to protect against HIV, creating the need to develop safe, effective, and acceptable prevention strategies that will help halt the spread of HIV infection globally. Promising candidates for inclusion into microbicides are lectins, which are carbohydrate-binding proteins that are present in a variety of plant, fungal, and cyanobacterial species. Over the last two decades, several lectins have been identified that potently block viral infection, being active against HIV and influenza virus (1-4). One such example is the extensively explored cyanobacterial lectin cyanovirin-N (CV-N), 2 which possesses virucidal properties against HIV types I and II, simian immunodeficiency virus, and other enveloped viruses like Ebola and influenza at nanomolar concentrations (5-7). Its anti-HIV activity is mediated by recognizing and interacting with high mannose glycans (Man-8, Man-9) that are present on the envelope glycoprotein gp120. Indeed, HIV-1 gp120 is highly glycosylated, and N-linked glycans account for approximately half of its molecular mass (8, 9). CV-N specifically binds the terminal Man␣(1-2)Man␣ epitopes on the D1 and D3 arms of Man-8 and Man-9 glycans (10 -14). The mechanism of action for mannose-binding lectins is assumed to involve the inability of the lectinbound gp120 to productively engage the host cell CD4 and CCR5 receptors, effectively preventing the necessary conformational changes required for membrane fusion and viral entry into the host cell. At present, efforts to develop lectins such as CV-N for therapeutic use are focused on topical applications in microbicides. All known anti-HIV lectins vary in their degrees of potency and some were found to ...